Aptamer Sciences is pursuing a stock consolidation that will merge every two common shares into one, in order to establish an appropriate share price and enhance corporate value.

According to a regulatory filing on the 23rd, Aptamer Sciences passed a resolution at its board meeting to consolidate two common shares with a par value of 500 KRW each into one common share with a par value of 1,000 KRW.

Once the consolidation is completed, the total number of issued common shares will be halved from the existing 61,039,242 shares to 30,519,621 shares. Class shares will also be adjusted from 920,000 to 460,000.

The company explained that this measure is a stock consolidation that only adjusts the number of shares and differs from a capital reduction, which involves a reduction of capital stock. Therefore, the company stated that there will be no change to shareholders' ownership percentages or the substantive value of the company.

■ To Be Presented at Extraordinary General Meeting on July 8… New Shares Listed on August 12

The stock consolidation proposal is scheduled to be presented at the extraordinary general meeting of shareholders on July 8. If approved, the effective date for the new shares will be July 24.

The trading suspension period is scheduled from July 22 to August 11, and the consolidated new shares will be listed on August 12.

Fractional shares of less than one that arise during the consolidation process will be paid in cash based on the closing price on the first trading day of the new shares. However, the schedule may change depending on the results of the shareholders' meeting and consultations with relevant authorities.

■ Stock Consolidation Trend in the Biotech Sector… "Future Performance and R&D Results Are Key"

There is an assessment that cases of adjusting the number of shares to establish appropriate stock prices and improve corporate images have been continuing, particularly in the biotech sector recently.

However, since the stock consolidation itself does not imply an improvement in corporate performance or a rise in stock price, future R&D achievements and business progress are cited as more critical variables.

Aptamer Sciences is a biotech company that researches and develops aptamer-based diagnostic and therapeutic platforms, and investors are paying attention to its future technological development achievements and commercialization progress.

[※ This article was written with the assistance of AI based on publicly available data and market information. The content included in this article is reference material for investment decisions and does not constitute a buy or sell recommendation for any specific stock or guarantee any returns. The stock market may fluctuate due to various variables, so investment decisions should be made based on the investor's own judgment and responsibility. Some information may be subject to interpretation or errors during the AI analysis process, so please be sure to verify regulatory filings and company announcements before making any final investment decisions.]